celecoxib has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cerella, C | 1 |
| Sobolewski, C | 1 |
| Chateauvieux, S | 1 |
| Henry, E | 1 |
| Schnekenburger, M | 1 |
| Ghelfi, J | 1 |
| Dicato, M | 1 |
| Diederich, M | 1 |
| Waskewich, C | 1 |
| Blumenthal, RD | 1 |
| Li, H | 1 |
| Stein, R | 1 |
| Goldenberg, DM | 1 |
| Burton, J | 1 |
2 other studies available for celecoxib and Hematologic Malignancies
| Article | Year |
|---|---|
COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; DNA Dama | 2011 |
Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
Topics: Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase I | 2002 |